Late Phase Trials

AstraZeneca (Serena 6)
Description Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression
Target Population ER- Positive HER2-Negative Breast Cancer
Type of medication Oral Medication
Phase of study III
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT04964934
AstraZeneca (Destiny 11)
Description Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Target Population Breast Neoplasms

Breast Cancer

HER2-positive Early Breast Cancer

Type of medication Intravenous Infusion
Phase of study III
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT05113251
Tempus Labs (ctDNA)
Description Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
Target Population Colorectal Cancer
Type of medication Observation
Phase of study N/A
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT05234177
Taiho (TAS-120)
Description Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Target Population Advanced Cholangiocarcinoma
Type of medication Oral Medication
Phase of study III
Available at Utah Cancer Specialists
Link https://www.clinicaltrials.gov/ct2/show/NCT04507503
Cardiff Oncology (ONSEMBLE)
Description Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
Target Population Colorectal Cancer

Metastatic Colorectal Cancer

Type of medication Intravenous Infusion and Oral Medication
Phase of study II
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT05593328
Mirati Therapeutics (KRYSTAL-10)
Description Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Target Population Advanced Colorectal Cancer

Metastatic Colorectal Cancer

Type of medication Intravenous Infusion and Oral Medication
Phase of study III
Available at Utah Cancer Specialists
Link https://www.clinicaltrials.gov/ct2/show/NCT04793958
Daiichi Sankyo ( TROPION –Lung08)
Description Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)
Target Population Metastatic Non-Small Cell Lung Cancer
Type of medication Intravenous Infusion
Phase of study III
Available at Utah Cancer Specialists
Link https://www.clinicaltrials.gov/ct2/show/NCT05215340
Incyte Corporation (InMIND)
Description A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
Target Population Follicular Lymphoma

Marginal Zone Lymphoma

Type of medication Intravenous Infusion and Oral Medication
Phase of study III
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT04680052
Epizyme, Inc. (Symphony-1)
Description Study in Subjects With Relapsed/Refractory Follicular Lymphoma
Target Population Relapsed/Refractory Follicular Lymphoma
Type of medication Intravenous Infusion and Oral Medication
Phase of study III
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT04224493
HUYABIO (HBI-8000)
Description Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma
Target Population Unresectable or Metastatic Melanoma

Progressive Brain Metastasis

Type of medication Intravenous Infusion and Oral Medication
Phase of study III
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT04674683
Pfizer (Starboard)
Description A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Target Population Melanoma
Type of medication Intravenous Infusion and Oral Medication
Phase of study III
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT04657991
Bristol-Myers Squibb (SUCCESSOR-1)
Description A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (Successor-1)
Target Population Relapsed or Refractory Multiple Myeloma
Type of medication Intravenous Infusion and Oral Medication
Phase of study III
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT05519085
Abbvie (TRANSFORM-2)
Description Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
Target Population Myleofibrosis
Type of medication Oral Medication
Phase of study III
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT04468984
Astellas Pharma (IMAB362)
Description A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
Target Population Pancreatic Cancer

Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma

Type of medication Intravenous Infusion
Phase of study II
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT03816163
Novartis Pharmaceuticals (PSMAddition)
Description An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition)
Target Population Prostatic Neoplasms
Type of medication Intravenous Infusion and Oral Medication
Phase of study III
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT04720157
Merus N.V. (MCLA-128)
Description Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
Target Population NSCLC Harboring NRG1 Fusion

Metastatic Castration- Resistant Prostate Cancer

Type of medication Intravenous Infusion and Oral Medication
Phase of study II
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT05588609
Merus N.V. (MCLA-128) (eNRGy)
Description A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion
Target Population Solid Tumors Harboring NRG1 Fusion

NSCLC Harboring NRG1 Fusion

Pancreatic Cancer Harboring NRG1 Fusion

NRG1 Fusion

Type of medication Intravenous Infusion
Phase of study III
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT02912949
Merck Sharp & Dome (MK-7339-007/KEYLINK-007)
Description A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer
Target Population Solid Tumors
Type of medication Intravenous Infusion and Oral Medication
Phase of study III
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT04123366
Merck Sharp & Dome (MK-4830-001)
Description Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors
Target Population Neoplasms
Type of medication Intravenous Infusion
Phase of study III
Available at Utah Cancer Specialists
Link https://clinicaltrials.gov/ct2/show/NCT03564691